INV501 / invIOs - LARVOL DELTA

invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma (GlobeNewswire) - "invIOs GmbH...and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma. The collaboration will be led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research and treatment. The research group will evaluate INV501 alone and in combination with the current standard of care (temozolomide or radiation) or anti-myeloid therapies in preclinical glioblastoma models. Depending on the outcome, further studies to understand the mechanisms of action of INV501 will be conducted."

Licensing / partnership • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors (GlobeNewswire) - "invIOs GmbH...publicly disclosed data for the first time from its high-potential small molecule program, INV501, showing that the novel compound can induce strong anti-tumor immune responses....The data show that INV501 significantly inhibits tumor growth, resulting in prolonged survival and increased cure rates even beyond the end of treatment when administered as an oral single agent in an orthotopic murine B16-SIY melanoma model. Similarly, in a breast cancer model using EO771 cells, tumor growth was significantly inhibited and survival prolonged even beyond the end of treatment. INV501 is orally available and has good bioavailability as well as a favorable pharmacokinetic profile."

Preclinical • Breast Cancer • Melanoma • Oncology • Skin Cancer • Solid Tumor